

A Translational Approach to Lung Cancer Research: From EGFRs to Wnt and Cancer Stem Cells

Adam Yagui-Beltrán, MD, and David M. Jablons, MD

Lung cancer remains the main cause of all cancer deaths in the United States. The prognosis for non-small cell lung cancer, despite advances in current therapies, is disappointing. Fortunately, we are steadily gaining significant insights into the heterogeneous molecular pathogenesis of lung cancer, which seems to occur in a stepwise manner, mainly secondary to tobacco smoking. With the emerging power of gene expression signatures for individual lung tumors and with the advancing field of stem cell biology and the paradigm of cancer stem cells, we are most certainly paving the way to developing novel tools for the early detection, chemoprevention, and treatment of these vastly morbid pathologies with enormous global burden. We will explore some of these issues and highlight how we are starting to translate them into clinically relevant tools for lung cancer patients. (Ann Thorac Cardiovasc Surg 2009; 15: 213–220)

Key words: non-small cell lung cancer, angiogenesis, epidermal growth factor receptor, novel targeted therapy, stem cell

Introduction

Lung cancer annually causes more than 1 million deaths worldwide.¹⁾ Despite efforts aimed at improving survival, delayed diagnosis and high relapse result in dismal prognosis. Overall lung cancer 5-year survival rates have only marginally changed over the past few decades; the current 5-year survival rate is about 15% in the United States and lower in developing countries.¹⁾ Many of the genetic and epigenetic anomalies found in lung cancer are also present in normal and preneoplastic tissue, suggesting a multistep process of epithelial carcinogenesis contemporary to tobacco smoking.²⁾ Good examples of the trans-

lation of pulmonary molecular events to the clinic include of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The growing field of stem cell research is becoming relevant in the understanding of lung carcinogenesis and to the development of novel targeted therapies.^{3–7)} Identifying individuals at high risk of lung cancer is crucial, and various biomarkers such as hypermethylation of certain lung cancer genes are being tested clinically.⁸⁾

The Molecular Basis of Lung Cancer

Lung carcinogenesis, like in the breast and colon, also follows a multistep oncogenic process.^{9–11)} Atypical adenomatous hyperplasia (AAH), a premalignant lesion thought to be a precursor to bronchioalveolar carcinoma (BAC), is frequently adjacent to invasive adenocarcinoma.^{12–15)} The elaborate collection of genetic abnormalities of disrupted pathways caused by environmental carcinogens, such as tobacco, result in the heterogeneous nature of lung cancers.

The Clinical Relevance of the Growth Factor Receptor Tyrosine Kinase

The tyrosine kinase activity of the EGFR was character-

From Department of Surgery, The University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

Received September 24, 2008; accepted for publication March 16, 2009
Address reprint requests to Adam Yagui-Beltrán, MD: Department of Surgery, The University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St., Box 1724, San Francisco, California 94143, USA.

Supported by The Kazan Foundation, The Bonnie J. Addario Lung Cancer Foundation, The Eileen D. Ludwig Endowed Fund for Thoracic Oncology Research, The Barbara Isackson Lung Cancer Research Fund, and the NIH/NCI R011R01CA093708-01A3 Grant.
©2009 The Editorial Committee of *Annals of Thoracic and Cardiovascular Surgery*. All rights reserved.

ized more than two decades ago.¹⁶⁾ The EGFR (HER1) is part of a bigger family of transmembrane receptors, including HER2, HER3, and HER4. They activate the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3, 4, 5 kinase (PI3k)/protein kinase B (PKB) signaling pathways, among others;¹⁷⁾ a disruption of these results in abnormal epithelial development, angiogenesis, and malignancy in most organs.^{18,19)} Moreover, high EGFR protein levels have been demonstrated in human lung, ovarian, and upper and lower gastrointestinal cancers.^{18–22)} HER1 and HER2 are overexpressed in about 70% and 30% of non-small cell lung cancers (NSCLCs), respectively. Tobacco-related dysplastic lung tissue has increased EGFR expression compared to hyperplastic and metaplastic lesions, suggesting a stage-dependent involvement in lung cancer.^{23–25)} Gefitinib and erlotinib are adenosine triphosphate (ATP) competitive inhibitors of the EGFR tyrosine kinase domain. Phase I trials of gefitinib demonstrated benefits in NSCLC. Two large phase II trials, Iressa Dose Evaluation in Advanced Lung Cancers (IDEALS) 1 and 2 in patients previously treated with conventional chemotherapy²⁶⁾ showed response rates in the range of 9%–19%, compared to only 7% for docetaxel. The efficacy of erlotinib in NSCLC was illustrated in the Br.21 trial²⁷⁾ by a higher median survival compared to placebo (6.7 months vs. 4.7 months) as well as a higher 1-year survival (31.2% vs. 21.5%). Interestingly, two large randomized trials, The Iressa NSCLC Trial Assessing Combination Treatment (INTACT) 1 and 2, showed that when gefitinib was used together with a first-line platinum-based agent, no survival advantage over chemotherapy alone was shown.^{28,29)} This may be explained by the antagonism between the cytotoxic effect of chemotherapy and the cytostatic (causing G₁ arrest) effects of the EGFR-TKI. The results of trials of sequential chemotherapy and EGFR-TKI will help clarify this. Combining erlotinib with conventional cytotoxic drugs, as in the case of gefitinib, did not prove to be useful. However, when erlotinib was combined with traditional chemotherapy in nonsmokers, a survival benefit was observed.^{29,30)} Mutations in the intracellular EGFR (tyrosine kinase) (EGFR TK) domain are common in never-a-smoker females of East Asian origin responding well to gefitinib.^{31–34)} The frequency of EGFR mutations is thought to be 39% and 48% among Japanese and Taiwanese patients, respectively, and around 3% to 9% in non-Asian U.S. patients. A new TK domain mutation (substitution of methionine for threonine at position 790 [T790M]) was found in four out of the seven patients

studied.^{35,36)} It is interesting that the T790M mutation is analogous to a secondary mutation in bcr-abl causing resistance to imatinib in chronic myeloid leukemia (CML) patients.^{37,38)} These examples demonstrate that TKIs play a beneficial role in certain NSCLC patient subgroups. However, they prompt more genetic and clinical studies to understand and exploit the heterogeneity of EGFR TK domain mutations to eventually design more-efficient therapeutic TKIs.

Monoclonal Antibodies against EGFR Tyrosine Kinase

Cetuximab has been shown to confer clinical benefits through disease control in 24.13% of the EGFR-expressing NSCLC patients treated.³⁹⁾ Data from phase I and II trials indicate that cetuximab combined with a first-line platinum-based agent is well tolerated, with rash being the only side effect.^{40–42)} The Lung Cancer Cetuximab Study (LUCAS) trial suggests that in first-line treatment of advanced NSCLC, the combination of cetuximab with cisplatin/vinorelbine shows beneficial clinical response with reasonable safety profiles compared to chemotherapy alone.^{43,44)} Such results led in 2004 to a large phase III multicenter trial, the First-Line ErbituX in lung cancer (FLEX) study, evaluating the efficacy of cetuximab in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone in patients with advanced untreated NSCLC. Accrual with 1,124 patients was completed in July 2007, and the specific clinical outcomes are being awaited.

Angiogenesis in Lung Cancer

Folkman et al. observed that tumors cannot grow beyond 2 mm without supporting vascularization.⁴⁵⁾ Endothelial cells produce vascular endothelial cell growth factor (VEGF), a mitogenic factor with a myriad of physiological functions,⁴⁶⁾ both during lung development in early life and during homeostasis in adulthood. Not surprisingly, abnormalities in the VEGF pathway can result in acute and chronic lung disease. Various VEGF families have been characterized: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental factor. VEGF ligands upon binding activate three structurally similar type III receptor tyrosine kinases: VEGF-receptor (VEGFR)-1, VEGFR-2, and VEGFR-3. Alternative gene splicing leads to several isoforms; these in turn may combine with the various receptors in a biologically heterogeneous manner. This is being exploited to develop targeted anti-

angiogenic therapies with minimal side effects.

Monoclonal Antibody against Angiogenesis

VEGF is overexpressed in many cancers, including lung cancer.^{47,48} Its expression in macrophages in the lung cancer microenvironment correlates to poor prognosis. Thus modulating angiogenesis in cancer is indeed an attractive therapeutic strategy. Bevacizumab, a recombinant humanized monoclonal VEGF antibody, has shown a synergistic survival advantage in colorectal cancer.⁴⁹ A lung cancer phase II trial studying the synergy of bevacizumab and paclitaxel/carboplatin showed a significant improvement in treatment response:⁵⁰ an overall response rate (ORR) of 31.5% vs. 18.8% in the bevacizumab arm compared to chemotherapy alone. Furthermore, a longer disease-free interval (7.4 months vs. 4.2) and overall survival time (17.7 months vs. 14.9) was seen in the bevacizumab group. The Eastern Cooperative Oncology Group (ECOG) phase III trial of paclitaxel/carboplatin with or without bevacizumab in untreated stage IIIB or metastatic NSCLC⁵⁰ showed a 27% vs. 10% response rate for the bevacizumab/chemotherapy group. Progression-free survival for the former group was 6.4 vs. 4.5 months, and the median survival was 12.5 vs. 10.2 months for the chemotherapy-alone arm. This is ECOG's gold standard treatment for advanced NSCLC. Other studies are under way to assess the role of bevacizumab combined with EGFR TKIs.⁵¹

Miscellaneous Antiangiogenesis Agents

The number of molecules under current clinical investigation include the platelet-derived growth factor (PDGF), the platelet-derived endothelial cell growth factor (PD-ECGF), various integrins, angiopoietins, and fibroblast growth factors (FGF)-1 and FGF-2.^{52,53} Below is a brief description of the ones most relevant to lung cancer.

VEGF-Trap (aflibercept)

Aflibercept is a soluble antiangiogenic decoy receptor composed of segments of extracellular domains VEGFR-1, VEGFR-2, and placental growth factor (PLGF) fused to the constant region (Fc) of human immunoglobulin (Ig) G1. Regeneron and Sanofi-Aventis have commenced an oncology development program to evaluate aflibercept with chemotherapy. Efficacy analysis showed evidence of tumor reduction and prolonged stable disease after aflibercept treatment as a single agent.⁵⁴ Under

way is a phase III study of aflibercept with second-line docetaxel for metastatic NSCLC (Sanofi-Aventis: NCT00532155).

SU11248 (sunitinib)

FDA-approved sunitinib targets various TK domains, including those of VEGFR, PDGF receptor (PDGFR), and c-Kit.⁵⁵ SU11248 in NSCLC is being assessed.⁵⁶

ZD6474

This is a low molecular weight inhibitor of the TK domain of EGFR and VEGFR-2. Its benefit in lung cancer was shown in a phase I and phase II study in metastatic tumors when used in conjunction with docetaxel.⁵⁷ Further trials will elucidate the role of ZD6474 either as a single agent or in combination with other chemotherapeutic agents.

BAY 43-9006 (sorafenib)

This agent is a potent TKI of VEGFR-2, VEGFR-3, B-Raf, and PDGFR- β . Several phase III clinical studies are assessing this agent in NSCLC; under way is a phase III randomized, double-blinded, placebo-controlled study sponsored by Bayer (NCT00449033) estimated to be concluded in 2010. It aims to evaluate the efficacy of cisplatin, gemcitabine, and sorafenib to cisplatin, gemcitabine, cisplatin, and placebo as first-line therapy for advanced NSCLC (specifically stage IIIB with pleural effusion and stage IV disease).

AG-013736

AG-013736 is an oral agent against a variety of TKs, such as VEGFR-1, VEGFR-2, VEGFR-3, c-Kit, and PDGFR- β . A phase I trial in metastatic NSCLC showed benefits in disease stabilization, and phase II trials are under way.⁵⁸

The Therapeutic Potential of Exploiting Epigenetic Changes in Lung Cancer

About 80 genes are hypermethylated, often simultaneously within an individual lung tumor.⁵⁹ These epigenetic changes can be translated into practical tools for early diagnosis. For example, the detection of hypermethylated DNA of the p16^{INK4a} gene in the sputum of patients with higher risks of developing lung cancer is useful. Approaches include identifying hypermethylated genes in lung tumors using a genome-wide strategy to create novel diagnostic and therapeutic tools.⁶⁰

Table 1. Immunotherapy in lung cancer

Trial	Year	Antigen type	Notes	Clinical outcome	Reference
Phases I/II ALVAC (n = 3 lung, 15 gastrointestinal)	2000	CEA	Nonreplicating canarypoxvirus expressing both human CEA and the B7.1 costimulatory molecule.	SD in 3/18	Liu et al. ⁷⁰⁾
Phase I (n = 19 NSCLC)	2004	Allogenic cell lines	NSCLC modified to express B7.1	SD in 5 and PR in 1.	Giangreco et al. ⁷¹⁾
Phase IIB BLP25 (n = 171 NSCLC)	2005	MUC1	MUC1 peptide with liposome adjuvant.	Evidence of survival benefit.	Butts et al. ⁷²⁾
Phase II trial (n = 86 NSCLC)	2006	Autologous tumor cells	GVAX: autologous tumor cells with GM-CSF secreting bystander cells.	Marginal prolonged remission was seen. No significant tumor response.	Nemunaitis et al. ⁶¹⁾
Phase II trial (n = 182 stage Ib/II NSCLC)	2007	MAGE-A3	Multicenter, double-blinded placebo-controlled study. Efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/ II NSCLC.	Some equivocal clinical benefits; further trials pending.	Vansteenkiste et al. ⁷³⁾
Phases I/II trial (n = 83 NSCLC)	2007	EGF	Pooled data from three nonrandomized studies. Neisseria meningitides P64k protein conjugated to a chemical adjuvant and EGF.	Survival benefit of 3.5 months for vaccinated patients compared to nonrandomized non- vaccinated.	González et al. ⁷⁴⁾


CEA, carcinoembryonic antigen; SD, stable disease, NSCLC, non-small cell lung cancer; PR, partial response; BLP, β -lipoprotein; MUC1, mucin 1; GM-CSF, granulocyte macrophage colony-stimulating factor; EGF, epidermal growth factor.

The Therapeutic Potential of Exploiting Immunomodulation in Lung Cancer

Two current immunotherapy strategies focus on active vaccination and adoptive T cell transfer. A recent phase I and phase II multicenter clinical trial using granulocyte macrophage colony-stimulating factors in advanced NSCLC demonstrated promising results that provide not only proof of principle, but also the basis for further studies.^{61,62)} Adoptive T cell transfer plays a role in the treatment of malignant melanoma; it is a process that entails the isolation and subsequent *in vitro* expansion of tumor infiltrating T cells followed by their reinfusion into the patient.^{63,64)} The challenge relies on the difficulty of isolating enough tumor-reactive T cells from lung cancer patients. A summary of clinical trials evaluating the role of immunotherapy in lung cancer is shown in Table 1.

The Therapeutic Potential of Targeting Wnt in Lung Cancer


Wnt signaling (Fig. 1) is crucial during the development and homeostasis of the pulmonary tree.^{65–68)} Wnt exerts a regulatory function in the stem cell compartment of many organs.^{69,70)} The clonogenic nature of human lung cancer was described almost 30 years ago. Clinical lung adenocarcinomas and small cell lung cancers (SCLC) were found to have a rare cellular population (< 1.5%) with the capacity to form agar colonies. When intracranially inoculated into athymic mice, they grew into originating malignant lesions. There is a link between the high expression of ABC transporters and drug resistance. Side population (SP) cells isolated by the efflux of Hoechst 33342 by ABC transporters with stem-cell characteristics have been demonstrated in both lung cell lines and clinical NSCLC. These data together with the heterogeneity and regionality of lung cancer demonstrated in



Yagui-Beltrán et al. 'The Wntless Gene: From Embryogenesis to Stem Cell Self-Renewal' Book: Stem Cells and Cancer. ISBN 978-1-1-60327-932-1

Fig. 1. The canonical Wnt transduction pathway.

Proteasomal degradation of β -catenin via its phosphorylation occurs in the absence of Wnt ligands. Downstream, Wnt target genes are maintained repressed ('OFF'). Degradation of active β -catenin is reduced upon the binding of Wnt's. Accumulation and translocation of β -catenin into the nucleus lead to binding to T cell factors and activation of target genes ('ON'). APC, adenomatous polyposis coli; Dvl, disheveled; GSK, glycogen synthase kinase; TCF, T cell factor.



Yagui-Beltrán et al. 'The Wntless Gene: From Embryogenesis to Stem Cell Self-Renewal' Book: Stem Cells and Cancer. ISBN 978-1-1-60327-932-1

Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. *Nature* 2004; 432: 324–31.

Fig. 2. Tissue homeostasis and carcinogenesis through stem cell cycling.

- A: Quiescent stem cell (SC) with inactive Wnt.
- B: Upon tissue trauma, Wnt transduction leads to activation of homeostatic SCs.
- C: These cells produce more pluripotent SCs as well as progenitor cells with limited proliferative power.
- D,A: That produces specialized differentiated cells (shown in orange, purple, and blue) to regenerate the tissue. Upon repair, SCs cycle into a quiescent state.
- E: Accumulation of oncogenic events may 'lock' activated SCs in a permanent Wnt-driven state, leading to cancer stem cells.

murine models⁷¹⁾ suggest the involvement of stem cells in the human lung (Fig. 2). The dissection of the precise molecular mechanisms by which Wnt regulates the initia-

tion, malignant transformation, and metastatic spread of lung progenitor, or stem-cell like cells becomes mandatory because of its enormous therapeutic potential.

Future Perspectives

In this article we have highlighted some of the most exciting translational therapeutic developments using various strategies with the aim to target lung cancer more precisely. We expect that in the next decade our understanding of the specific mechanisms governing lung carcinogenesis within individual pulmonary microenvironments will grow further. Thus we will be able to successfully translate these mechanisms into novel clinically and relevant tools for the diagnosis, screening, and management of lung cancer patients. We greatly hope that through the identification and targeting of unique and phenotypically defined lung cancer stem-cell populations that possess the potential to result in tumor recurrence, we will be able to design new targeted therapies that will circumvent many of the side effects of current cytotoxics with implicit improvement in the quality of life for our lung cancer patients and increased disease-free survival rates.

References

- Jemal, A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2008. *CA Cancer J Clin* 2008; **58**: 71–96.
- Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. *Cancer Res* 2000; **60**: 1949–60.
- Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, et al. Cancerous stem cells can arise from pediatric brain tumors. *Proc Natl Acad Sci U S A* 2003; **100**: 15178–83.
- Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. *Cancer Res* 2004; **64**: 7011–21.
- Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. A distinct “side population” of cells in human tumor cells: implications for tumor biology and therapy. *Cell Cycle* 2005; **4**: 203–5.
- Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2⁺ and ABCG2⁻ cancer cells are similarly tumorigenic. *Cancer Res* 2005; **65**: 6207–19.
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 2003; **100**: 3983–8.
- Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. *Cancer Res* 2006; **66**: 3338–44.
- Fujiwara T, Stolker JM, Watanabe T, Rashid A, Longo P, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. *Am J Pathol* 1998; **153**: 1063–78.
- Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988; **319**: 525–32.
- Beckmann MW, Niederacher D, Schnürch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. *J Mol Med* 1997; **75**: 429–39.
- Yoshida Y, Shibata T, Kokubu A, Tsuta K, Matsuno Y, et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. *Lung Cancer* 2005; **50**: 1–8.
- Saad RS, Liu Y, Han H, Landreneau RJ, Silverman JF. Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. *Mod Pathol* 2004; **17**: 1235–42.
- Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. *Am J Clin Pathol* 1999; **111**: 610–22.
- Okubo K, Mark EJ, Flieder D, Wain JC, Wright CD, et al. Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. *J Thorac Cardiovasc Surg* 1999; **118**: 702–9.
- Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. *J Biol Chem* 1980; **255**: 4834–42.
- Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. *J Clin Oncol* 2001; **19** (18 Suppl): 32–40S.
- Downward J, Yarden Y, Mayes E, Scrace G, Totty N, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. *Nature* 1984; **307**: 521–7.
- Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. *Genes Dev* 1998; **12**: 3663–74.
- Straight SW, Herman B, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. *J Virol* 1995; **69**: 3185–92.
- Menzo S, Clementi M, Alfani E, Bagnarelli P, Iacovacci S, et al. Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. *Virology* 1993; **196**: 878–82.
- Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr

- virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. *J Virol* 1995; **69**: 4390–8.
23. Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, et al. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. *Clin Cancer Res* 2002; **8**: 734–44.
 24. Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. *Clin Cancer Res* 2002; **8**: 54–60.
 25. Meert AP, Verdebout JM, Martin B, Ninane V, Feoli F, et al. Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions. *Eur Respir J* 2003; **21**: 611–5.
 26. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. *J Clin Oncol* 2003; **21**: 2237–46.
 27. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005; **353**: 123–32.
 28. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. *J Clin Oncol* 2004; **22**: 785–94.
 29. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. *J Clin Oncol* 2004; **22**: 777–84.
 30. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2005; **23**: 5892–9.
 31. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004; **304**: 1497–500.
 32. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004; **350**: 2129–39.
 33. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004; **101**: 13306–11.
 34. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 2005; **97**: 339–46.
 35. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Koehler O, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2005; **352**: 786–92.
 36. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005; **2**: e73.
 37. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science* 2001; **293**: 876–80.
 38. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. *Gastroenterology* 2004; **127**: 294–9.
 39. Lynch TJ, Lilenbaum R, Bonomi P, Ansari R, Govindan R, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). *Proc Am Soc Clin Oncol* (Post-Meeting Edition) 2004; **22** (No 14S [July 15 Suppl]): 7084.
 40. Kelly K, Hanna N, Rosenberg A, Bunn PA, Needle MN. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. *J Clin Oncol* 2005; **23**: 8786–93.
 41. Robert F, Blumenschein G, Dicke K, Tseng J, Saleh MN, et al. Phase IB/IIA study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced stage IV non-small cell lung cancer. *Proc Am Soc Clin Oncol* 2003; **22**: 2587.
 42. Kim ES, Mauer AM, Tran HT, Liu D, Gladish G, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. *Proc Am Soc Clin Oncol* 2003; **22**: 642.
 43. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. *Ann Oncol* 2008; **19**: 362–9.
 44. Rosell R, Daniel C, Ramlau R, Szczesna A, Constenla M, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). *Proc Am Soc Clin Oncol* (Post-Meeting Edition) 2004; **23** (14 Suppl): 618, abstr. 7012.
 45. Folkman J. What is the evidence that tumors are angiogenesis dependent? *J Natl Cancer Inst* 1990; **82**: 4–6.
 46. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev* 2004; **25**: 581–611.
 47. Bando H, Brokelmann M, Toi M, Alitalo K, Sleeman JP, et al. Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human

- malignant tumor tissues. *Int J Cancer* 2004; **111**: 184–91.
48. Kaya A, Poyraz B, Celik G, Ciledag A, Gulbay BE, et al. Vascular endothelial growth factor in benign and malignant pleural effusions. *Arch Bronconeumol* 2005; **41**: 376–9.
 49. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004; **350**: 2335–42.
 50. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol* 2004; **22**: 2184–91.
 51. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. *J Clin Oncol* 2005; **23**: 2544–55.
 52. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. *Nature* 1989; **338**: 557–62.
 53. Kitadai Y, Ellis LM, Tucker SL, Greene GF, Bucana CD, et al. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. *Am J Pathol* 1996; **149**: 1541–51.
 54. Dupont J, Aghajanian C, Sabbatini P, Spriggs DR. New agents for the treatment of ovarian cancer: the next generation. *Int J Gynecol Cancer* 2005; **15** (Suppl 3): 252–7.
 55. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, et al. *In vivo* antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. *Clin Cancer Res* 2003; **9**: 327–37.
 56. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. *Mol Cancer Ther* 2003; **2**: 471–8.
 57. Heymach JV. ZD6474—clinical experience to date. *Br J Cancer* 2005; **92** (Suppl 1): S14–20.
 58. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. *J Clin Oncol* 2005; **23**: 5464–73.
 59. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. *Cancer Res* 2001; **61**: 249–55.
 60. Shames DS, Girard L, Gao B, Sato M, Lewis CM, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. *PLoS Med* 2006; **3**: e486.
 61. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. *Cancer Gene Ther* 2006; **13**: 555–62.
 62. Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. *J Natl Cancer Inst* 2004; **96**: 326–31.
 63. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. *Science* 2004; **305**: 200–5.
 64. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* 2006; **314**: 126–9.
 65. Morrissey EE. Wnt signaling and pulmonary fibrosis. *Am J Pathol* 2003; **162**: 1393–7.
 66. Weidenfeld J, Shu W, Zhang L, Millar SE, Morrissey EE. The WNT7b promoter is regulated by TTF-1, GATA6, and Foxa2 in lung epithelium. *J Biol Chem* 2002; **277**: 21061–70.
 67. Li C, Xiao J, Hormi K, Borok Z, Minoo P. Wnt5a participates in distal lung morphogenesis. *Dev Biol* 2002; **248**: 68–81.
 68. Shu W, Jiang YQ, Lu MM, Morrissey EE. Wnt7b regulates mesenchymal proliferation and vascular development in the lung. *Development* 2002; **129**: 4831–42.
 69. Owens DM, Watt FM. Contribution of stem cells and differentiated cells to epidermal tumours. *Nat Rev Cancer* 2003; **3**: 444–51.
 70. Liu BY, McDermott SP, Khwaja SS, Alexander CM. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. *Proc Natl Acad Sci U S A* 2004; **101**: 4158–63.
 71. Giangreco A, Groot KR, Janes SM. Lung cancer and lung stem cells: strange bedfellows? *Am J Respir Crit Care Med* 2007; **175**: 547–53.
 72. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. *J Clin Oncol* 2005; **23**: 6674–81.
 73. Vansteenkiste J, Zielinski M, Linder A. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non-Small Cell Lung Cancer (NSCLC). *Proc Am Soc Clin Oncol* (Part I) 2007; **25** (18S): 7554.
 74. González G, Crombet T, Neningen E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. *Hum Vaccin* 2007; **3**: 8–13.